Elaine Jones is currently a vice president, Venture Capital, at Pfizer Ventures. Since joining the team in 2008, she is responsible for making venture investments for Pfizer and currently manages investments in Arrakis, Autifony (UK), Blade Therapeutics, eFFECTOR, Jnana, Mersana, MISSION Therapeutics (UK), NextCure, Nimbus, Second Genome and Storm Therapeutics (UK). Dr. Jones brings 19 years of VC experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PV team. Prior to Pfizer, Dr. Jones was a general partner with the venture fund, EuclidSR Partners. Dr. Jones began her investing career in 1999 at S.R. One, GlaxoSmithKline’s corporate fund. Previously, she served as director, Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.